Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarilumab (Primary) ; Prednisone
  • Indications Polymyalgia rheumatica
  • Focus Registrational; Therapeutic Use
  • Acronyms SAPHYR
  • Sponsors Sanofi
  • Most Recent Events

    • 15 Nov 2023 Results assessing the pharmacokinetic-pharmacodynamic relationships of sarilumab exposure with key efficacy, and safety endpoints in patients with polymyalgia rheumatica, presented at the ACR Convergence 2023.
    • 05 Oct 2023 Results assessing efficacy of Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper published in the New England Journal of Medicine
    • 03 Jun 2023 Results of post-hoc analysis assessing the proportion of patients achieving sustained remission up to week 52 from week 16 and from week 24, presented at the 24th Annual Congress of the European League Against Rheumatism.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top